NCT03367260|Completed
Loading search results
Sponsor study identifier
observational
115
1 country
1
Study Start
October 19, 2017
Actual (reported)Primary Completion
January 4, 2019
Actual (reported)Study Completion
January 4, 2019
Actual (reported)The primary objective of this study is to apply best-practice stated-preference methods to quantify the extent to which women with ovarian cancer accept the risks, side effects, and out-of-pocket costs associated with treatment in return for progression-free survival benefit afforded by a treatment, regardless of whether there is an overall survival benefit.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 4, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 19, 2017
Actual (reported)November 20, 2017
Actual (reported)December 8, 2017
Actual (reported)January 4, 2019
Actual (reported)January 4, 2019
Actual (reported)Preference between two treatment alternatives as measured by discrete choice experiment (DCE).
In the DCE, women are asked to choose between two hypothetical treatment scenarios characterized using 7 attributes (treatment schedule, out of pocket cost, peripheral neuropathy, nausea and vomiting, fatigue, progression-free survival and overall survival).
baseline
Survey of patient preferences for treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
A maximum on 300 subjects will be enrolled on this study. All subjects will have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer and at least 100 of them will have been treated with a PARPi.
Duke University Medical Center
Durham, North Carolina, 27710, United States
Laura Havrilesky, MD
Duke University
115 participants (actual enrollment reported by the registry).
First Submitted
November 20, 2017
First Posted
December 8, 2017
Study Start
October 19, 2017
Actual (reported)Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
Contact the study team to confirm eligibility.
Primary Completion
January 4, 2019
Actual (reported)Study Completion
January 4, 2019
Actual (reported)Last Updated
June 27, 2019
Record last verified: 2019-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: